ID
14490
Description
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00639691
Link
https://clinicaltrials.gov/show/NCT00639691
Keywords
Versions (1)
- 4/18/16 4/18/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
April 18, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Asthma NCT00639691
Eligibility Asthma NCT00639691
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
comorbidity
Data type
boolean
Alias
- UMLS CUI [1]
- C0009488
Description
pregnancy or lactation
Data type
boolean
Alias
- UMLS CUI [1]
- C0032961
- UMLS CUI [2]
- C0006147
Description
lung disease
Data type
boolean
Alias
- UMLS CUI [1]
- C0024115
Description
anaphylactoid or anaphylactic reaction
Data type
boolean
Alias
- UMLS CUI [1]
- C0340865
- UMLS CUI [2]
- C0002792
Description
warfarin immunomodulatory therapy or antiplatelet therapy
Data type
boolean
Alias
- UMLS CUI [1]
- C0043031
- UMLS CUI [2]
- C1963758
- UMLS CUI [3]
- C1096021
Similar models
Eligibility Asthma NCT00639691
- StudyEvent: Eligibility
C0040223 (UMLS CUI [1,2])
C0155877 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0002792 (UMLS CUI [2])
C1963758 (UMLS CUI [2])
C1096021 (UMLS CUI [3])